Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02554812 · ClinicalTrials.gov registry record · Phase 1
A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 409
- Enrollment target
NCT02554812 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 409 participants.
The verdict
NCT02554812, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 409 participants
- Enrollment target
Study Summary
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications.
Interventions
- DRUG Avelumab
- DRUG Utomilumab
- DRUG CMP-001
- DRUG PF-04518600
- DRUG PD 0360324
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 409 participants |
| Start Date | 2015-11-09 |
| Est. Completion | 2023-03-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02554812
The ClinicalTrials.gov registry entry for NCT02554812 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 409 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Avelumab is the first listed.
NCT02554812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02554812 about?
NCT02554812 is a clinical study titled "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)". This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to a...
What is the current status of trial NCT02554812?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 409 participants. The study started on 2015-11-09. Estimated completion is 2023-03-23.
What interventions are being tested in trial NCT02554812?
The interventions under investigation include: Avelumab (DRUG), Utomilumab (DRUG), CMP-001 (DRUG), PF-04518600 (DRUG), PD 0360324 (DRUG).
Who is sponsoring clinical trial NCT02554812?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.